Clinical nanomedicine: A solution to the chemotherapy conundrum in pediatric leukemia therapy

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 168-178

  Krishnan, V ^a,b   Rajasekaran, A K ^a,b  

^a UNIVERSITY OF DELAWARE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; NANOMEDICINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84893775282     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.174     Document Type: Review

References (75)

1. F acts 2012. The Leukemia & Lymphoma Society. . Accessed 18 November 2013.
2. Mody, R. et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood 111, 5515-5523 (2008).
3. Davis, M.E., Chen, Z.G. & Shin, D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008).
4. Kamaly, N., Xiao, Z., Valencia, P.M., Radovic-Moreno, A.F. & Farokhzad, O.C. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 41, 2971-3010 (2012).
5. Henderson, E.S. & Samaha, R.J. Evidence that drugs in multiple combinations have materially advanced the treatment of human malignancies. Cancer Res. 29, 2272-2280 (1969).
6. DeVita, V.T. Principles of chemotherapy. In: Principles and Practice of Oncology 3rd edn. (eds. DeVita, V.T., Rosenberg, S.) (Lippincott, Philadelphia, PA, 1989).
7. Stuart, F.A., Segal, T.Y. & Keady, S. Adverse psychological effects of corticosteroids in children and adolescents. Arch. Dis. Child. 90, 500-506 (2005).
8. Von Hoff, D.D., Rozencweig, M., Layard, M., Slavik, M. & Muggia, F.M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 62, 200-208 (1977).
9. Lipshultz, S.E., Colan, S.D., Gelber, R.D., Perez-Atayde, A.R., Sallan, S.E. & Sanders, S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324, 808-815 (1991).
10. Sandler, S.G., Tobin, W. & Henderson, E.S. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 19, 367-374 (1969).
11. Moe, P.J. & Holen, A. High-dose methotrexate in childhood all. Pediatr. Hematol. Oncol. 17, 615-622 (2000).
12. Cheson, B.D. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 13, 2431-2448 (1995).
13. Baker, W.J., Royer, G.L. Jr & Weiss, R.B. Cytarabine and neurologic toxicity. J. Clin. Oncol. 9, 679-693 (1991).
14. Thomas, D.A. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396-4407 (2004).
15. Müller, H.J. & Boos, J. Use of L-asparaginase in childhood ALL. Crit. Rev. Oncol. Hematol. 28, 97-113 (1998).
16. Kellie, S.J. et al. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer 67, 1070-1075 (1991).
17. Bixby, D. & Talpaz, M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am. Soc. Hematol. Educ. Program 461-476 (2009).
18. Angiolillo, A.L., Yu, A.L., Reaman, G., Ingle, A.M., Secola, R. & Adamson, P.C. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report. Pediatr. Blood Cancer 53, 978-983 (2009).
19. Raetz, E.A. et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed Acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: Results from children's oncology group (COG) study ADVL04P2. In 53rd ASH Annual Meeting and Exposition (American Society of Hematology, San Diego, CA, 2011).
20. Smith, M.A. Update on developmental therapeutics for acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 4, 175-182 (2009).
21. National Nanotechnology Initiative. Nanotechnology 101. http://www.nano.gov/nanotech-101.
22. F orssen, E.A. & Ross, M.E. Daunoxome® treatment of solid tumors: Preclinical and clinical investigations. J. Liposome Res. 4, 481-512 (1994).
23. Mross, K. et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: An open-label, single-dose study. Cancer Chemother. Pharmacol. 54, 514-524 (2004).
24. F eldman, E.J. et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 36, 1283-1289 (2012).
25. O'Brien, M.E. et al.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 440-449 (2004).
26. Valle, J.W. et al. A phase 2 study of SP1049C, doxorubicin in P-glycoproteintargeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 29, 1029-1037 (2011).
27. Matsumura, Y. et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91, 1775-1781 (2004).
28. F DA approves Marqibo to treat rare type of leukemia. Accessed 30 April 2013.
29. F asol, U. et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann. Oncol. 23, 1030-1036 (2012).
30. National Library of Medicine. . Accessed 8 August 2013.
31. Montana, M., Ducros, C., Verhaeghe, P., Terme, T., Vanelle, P. & Rathelot, P. Albumin-bound paclitaxel: The benefit of this new formulation in the treatment of various cancers. J. Chemother. 23, 59-66 (2011).
32. Lee, K.S. et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108, 241-250 (2008).
33. Lee, J.L. et al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest. New Drugs 30, 1984-1990 (2012).
34. Kato, K. et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30, 1621-1627 (2012).
35. Galic, V.L., Wright, J.D., Lewin, S.N. & Herzog, T.J. Paclitaxel poliglumex for ovarian cancer. Expert Opin. Investig. Drugs 20, 813-821 (2011).
36. Dark, G.G. et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the national cancer institute of Canada clinical trials group. J. Clin. Oncol. 23, 1859-1866 (2005).
37. Zamboni, W.C. et al. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin. Cancer Res. 15, 1466-1472 (2009).
38. Weiss, G.J. et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrincontaining polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 31, 986-1000 (2013).
39. Hamaguchi, T. et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 16, 5058-5066 (2010).
40. Plummer, R. et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104, 593-598 (2011).
41. Ishida, T. et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 112, 15-25 (2006).
42. Koide, H. et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 362, 197-200 (2008).
43. Lu, W., Wan, J., She, Z. & Jiang, X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release 118, 38-53 (2007).
44. Tagami, T., Uehara, Y., Moriyoshi, N., Ishida, T. & Kiwada, H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J. Control. Release 151, 149-154 (2011).
45. Kaminskas, L.M., McLeod, V.M., Porter, C.J. & Boyd, B.J. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J. Pharm. Sci. 100, 5069-5077 (2011).
46. Huang, X. & Brazel, C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73, 121-136 (2001).
47. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug. Chem. 21, 797-802 (2010).
48. Chrastina, A., Massey, K.A. & Schnitzer, J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 421-437 (2011).
49. Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. & Davis, M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104, 15549-15554 (2007).
50. He, H. et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 34, 5344-5358 (2013).
51. Matsumura, Y. et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15, 517-525 (2004).
52. Sankhala, K.K. et al. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin [abstract]. J. Clin. Oncol. 27(suppl.), 15s (2009).
53. Nemunaitis, J., Senzer, N., Bedell, C., Nunan, R., Sleer, L. & Chang, E. A phase I study of escalating doses of SGT-53 for intravenous infusion of patients with advanced solid tumors. Mol. Ther. 17, S226 (2009).
54. Hrkach, J. et al. Preclinical development and clinical translation of a PSMAtargeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39 (2012).
55. Davis, M.E. The first targeted delivery of siRNA in humans via a selfassembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm. 6, 659-668 (2009).
56. Choi, H.S. et al. Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165-1170 (2007).
57. Moghimi, S.M., Hunter, A.C. & Murray, J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
58. Jiang, W., Kim, B.Y., Rutka, J.T. & Chan, W.C. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3, 145-150 (2008).
59. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9, E128-E147 (2007).
60. Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 249-255 (2007).
61. Verma, A. & Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small 6, 12-21 (2010).
62. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. & Folkman, J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150, 815-821 (1997).
63. Pulè, M.A., Gullmann, C., Dennis, D., McMahon, C., Jeffers, M. & Smith, O.P. Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. Br. J. Haematol. 118, 991-998 (2002).
64. Marquet, F., Tung, Y.S., Teichert, T., Ferrera, V.P. & Konofagou, E.E. Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PLoS ONE 6, e22598 (2011).
65. Oltra, N.S., Swift, J., Adbullah, M., Rajagopal, K., Loverdea, S.M. & Discher, D.E. Filomicelles in nanomedicine -from flexible, fragmentable, and ligandtargetable drug carrier designs to combination therapy for brain tumors. J. Mater. Chem. B 1, 5177 (2013).
66. Owens, D.E. 3rd & Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006).
67. Hamad, I., Hunter, A.C., Szebeni, J. & Moghimi, S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225-232 (2008).
68. Yamamoto, Y., Nagasaki, Y., Kato, Y., Sugiyama, Y. & Kataoka, K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J. Control. Release 77, 27-38 (2001).
69. Wang, J., Byrne, J.D., Napier, M.E. & DeSimone, J.M. More effective nanomedicines through particle design. Small 7, 1919-1931 (2011).
70. Krishnan, V. et al. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: A novel application in pediatric nanomedicine. Mol. Pharm. 10, 2199-2210 (2013).
71. Allen, T.M. & Cleland, L.G. Serum-induced leakage of liposome contents. Biochim. Biophys. Acta 597, 418-426 (1980).
72. Mortensen, B.T. et al. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br. J. Haematol. 102, 458-464 (1998).
73. Torchilin, V.P. et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: Fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511, 397-411 (2001).
74. Weissleder, R., Kelly, K., Sun, E.Y., Shtatland, T. & Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418-1423 (2005).
75. Lancet, J.E. et al. CPX-351 is effective in newly diagnosed older patients with AML and with multiple risk factors [abstract]. In 54th ASH Annual Meeting and Exposition, Vol. 120 (Blood-ASH Annual Meeting Abstracts, Atlanta, GA, 2012).